4 completed. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 1 | Completed 1 |
Follow DFMO: new trials by email Literature Review of DFMO trials Research Report on DFMO
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission DFMO - Neuroblastoma | Phase 2 | Completed | Giselle Sholler | 140 | 2015-03-05 | 2024-08-06 |
| Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma DFMO, Bortezomib - Neuroblastoma Recurrent | Phase 1 / Phase 2 | Completed | Giselle Sholler | 16 | 2014-06-06 | 2024-08-06 |
| Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer Aspirin, Eflornithine, Laboratory Biomarker Analysis - Adenomatous Polyp | Phase 2 | Completed | National Cancer Institute (NCI) | 107 | 2009-08-20 | 2019-09-04 |
| Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis Celecoxib, Placebo, eflornithine - Colorectal Cancer, Familial Adenomatous Polyposis | Phase 2 | Completed | National Cancer Institute (NCI) | 205 | 2001-12-13 | 2020-09-29 |
Adenomatous Polyposis Coli (1) · Adenomatous Polyps (1) · Colorectal Neoplasms (1) · Neuroblastoma (1)
Giselle Sholler (2) · National Cancer Institute (NCI) (2)
United States (4)
Frank A Sinicrope (1) · Giselle Saulnier-Sholler, MD (1) · Kathleen Neville, MD (1) · Patrick Lynch (1)
PMID 25792707, PMID 32391579, PMID 32506485, PMID 34522028, PMID 37883734, PMID 38917371
P30CA015083 (1), P30CA016672 (1), R01CA113681 (1)